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Antibodies that neutralize autologous transmitted/
founder (TF) HIV occur in most HIV-infected individ-
uals and can evolve to neutralization breadth. Autol-
ogous neutralizing antibodies (nAbs) against neutral-
ization-resistant (Tier-2) viruses are rarely induced by
vaccination. Whereas broadly neutralizing antibody
(bnAb)-HIV-Envelope structures have been defined,
the structures of autologous nAbs have not. Here,
we show that immunization with TF mutant Envs
gp140 oligomers induced high-titer, V5-dependent
plasma neutralization for a Tier-2 autologous TF
evolved mutant virus. Structural analysis of autolo-
gous nAb DH427 revealed binding to V5, demon-
strating the source of narrow nAb specificity and
explaining the failure to acquire breadth. Thus, oligo-
meric TF Envs can elicit autologous nAbs to Tier-2
HIVs, but induction of bnAbs will require targeting
of precursors of B cell lineages that can mature to
heterologous neutralization.INTRODUCTION
The HIV-1 envelope protein (Env) is the primary target of neutral-
izing antibodies (nAbs) (Wyatt and Sodroski, 1998; Zhou et al.,
2007). One major obstacle to developing an effective HIV-1 vac-
cine is finding an immunogen that can elicit broadly nAbs (bnAbs)with the capacity to overcome variability of the virus and to retain
neutralizing activity for most circulating HIV-1 strains (Burton
et al., 2012; Mascola and Haynes, 2013).
Between 3 and 12 months after HIV-1 transmission, most in-
fected individuals develop autologous, strain-specific nAbs to
the transmitted/founder (TF) virus and TF variants (Ariyoshi
et al., 1992; Richman et al., 2003; Wei et al., 2003). The autolo-
gous nAb response drives viral escape and stimulates additional
specificities of nAbs that neutralize escape viruses (Richman
et al., 2003; Wei et al., 2003). This antibody virus co-evolution
persists throughout infection, and in 20% of individuals, it
leads, after years of infection, to development of high levels of
bnAbs (Doria-Rose et al., 2010; Gray et al., 2011; Liao et al.,
2013a; Tomaras et al., 2011; Walker et al., 2011).
Two recent studies mapped the ontogeny of bnAbs and TF
viruses from the time of transmission to bnAb development
and showed that bnAbs arise from autologous nAb B cell
clonal lineages but that only a small number of the autologous
nAb lineages ultimately evolve to neutralization breadth (Do-
ria-Rose et al., 2014; Liao et al., 2013a). Identification of im-
munogens that can induce nAbs against autologous, neutral-
ization-resistant (Tier-2) viruses is a major challenge for HIV
vaccine design, and examples of vaccine-matched, Tier-2
nAb responses elicited by vaccination in primates are few
(Sanders et al., 2015; Willey et al., 2003). Moreover, no vac-
cine-induced Tier-2 nAbs have yet been isolated and charac-
terized, nor have structures of their Env complexes been
determined.
CAP206 is an HIV-infected African individual who later
developed gp41-targeted bnAbs (Gray et al., 2009a; MorrisCell Reports 14, 43–54, January 5, 2016 ª2016 The Authors 43
et al., 2011). As a critical first step in HIV vaccine design, we
sought to map the autologous nAb response and to elicit
Tier-2 nAbs that mimicked this early autologous nAb response
by immunization with Env proteins isolated over the course of
infection. We report here that immunization of rhesus ma-
caques with HIV-1 TF variants from CAP206 induced strain-
specific nAbs to vaccine-matched Tier-2 autologous viruses
in three of six animals. After only two immunizations, one ma-
caque had a high-titer nAb response that targeted the CD4-
binding site (bs) and mimicked the autologous nAb response
observed in CAP206. We isolated a vaccine-induced nAb
clonal lineage (DH427) that potently neutralized the Tier-2
CAP206 6-month virus and recapitulated the observed plasma
neutralization response. A crystal structure of DH427 in com-
plex with HIV Env showed that DH427 bound close to the
CD4bs but also interacted with variable regions in the HIV
Env (loop E and V5-loop), explaining the restricted neutraliza-
tion breadth and the failure of DH427 to evolve to heterologous
neutralization.
RESULTS
Immunization of Rhesus Macaques Elicits Tier-2
Autologous Neutralization
We tracked the evolution of the CAP206 env gene from the TF vi-
rus until 39 months after transmission (Figure 1A). We selected
the CAP206 TF and six additional representative mutant env
genes from 2-, 6-, 12-, 21-, 24-, and 30-month time points and
produced them as recombinant gp140 oligomers that were pre-
dominately trimers (Figure S1A). The antigenic and functional
epitopes expressed on each of the recombinant CAP206 Envs
were determined by SPR assays (Figure S1B). All Envs bound
to CD4 and mAb A32, which binds well to uncleaved trimers,
and the magnitude of CD4 binding increased in Envs isolated
from later CAP206 time points (Figure S1B). The seven Envs
showed binding to a panel of nAbs and bound to 17b, an anti-
body that binds to the CD4-induced conformation of Env, in
the absence of CD4 (Figure S2). Some Envs lacked binding of
bnAbs that target the CD4bs, and others only reacted weakly,
indicating disruption of canonical CD4bs bnAb epitopes in the
CAP206 Envs.
We immunized six rhesus macaques with a cocktail of
all seven CAP206 recombinant gp140 oligomers and collected
plasma and PBMCs before the first immunization and 2 weeks
after each subsequent immunization (Figure 1B). We tested
plasma from Env-immunized animals for the presence of
anti-HIV neutralizing activity using the TZM-bl pseudovirus
assay. Plasmas collected before the first immunization
(week 0) and 2 weeks after the last immunization (week 38)
were tested for neutralization of heterologous, neutralization-
sensitive (Tier-1) isolates MN (clade B) and MW965 (clade
C) and of autologous, Tier-2, vaccine-matched isolates
of the seven CAP206 Envs (Figures 1C and S3A). We
observed potent neutralization titers against the Tier-1 MN
and MW965 viruses in all animals. Low levels of neutralizing
activity against Tier-2 autologous viruses were present in
two animals (Figures 1C and S3B). One animal, rhesus ma-
caque 5173, had potent plasma neutralization activity against44 Cell Reports 14, 43–54, January 5, 2016 ª2016 The Authorsthe Tier-2 autologous 6-month CAP206 TF variant virus (Fig-
ures 1C and S3B).
Neutralization of the 6-month virus emerged in 5173 plasma
2 weeks after the second immunization and was boosted by re-
petitive immunization and persisted throughout the remainder of
the immunization regimen (Figure 1D). Plasma neutralization re-
sponses waned 20 months after the last immunization (data not
shown). Thus, immunization with CAP206 Envs effectively eli-
cited potent Tier-1 heterologous virus neutralization in all six an-
imals and low levels of Tier-2 nAbs in two of them; in one animal,
it rapidly induced an early and robust neutralization response to
an autologous Tier-2 virus.
Immunization-Induced Neutralization Mimics Early
Autologous CAP206 Plasma Neutralization Response
Autologous Tier-2 neutralization in macaque 5173 was specific
for the CAP206 6-month virus. Env sequences that were isolated
from later time points post-infection from CAP206 contained
numerous mutations that were candidate sites of immune pres-
sure. Two of the very first observed Env sequence changes re-
tained in the 6-month Env were in the V1/V2 and V5 regions
(Figure 2A).
Closer inspection of the V5 sequences revealed extensive di-
versity in this region among longitudinal CAP206 Envs. Specif-
ically, the 6-month Env had a five-amino-acid deletion and
lacked a predicted glycosylation site at position 463 (Figure 2B).
To determine whether 5173 neutralization of the 6-month
CAP206 virus targeted V5, we engineered a mutation in the
6-month virus that introduced a glycosylation site at position
463 (S463N). We found persistent plasma neutralization of the
wild-type 6-month virus for samples across the full immunization
period but no neutralization of the glycosylation site variant
(Figure 2C).
To examine the role of mutations in the V5 loop in early autol-
ogous escape of the infecting virus in CAP206, we tested
CAP206 plasma isolated post-infection for the ability to
neutralize the autologous 2-month and 12-month viral isolate.
Early plasma samples exclusively neutralized the 2-month virus,
and only later plasma samples acquired neutralization activity for
the 12-month virus (Figure 2D). When we reverted the 12-month
V5 region back to the 2-month sequence, the chimeric virus
became sensitive to neutralization by early CAP206 plasma
time points. Reverting mutations in the V1V2 in the 12-month
back to the 2-month did not have any effect on early neutraliza-
tion. Thus, the V5 loop was a target for autologous nAbs in
CAP206 after infection and a V5-dependent autologous nAb
response was elicited in a rhesus macaque by immunization
with a CAP206 TF variant.
Immunization Elicited CD4bs Autologous nAbs
We isolated single Env-specific memory B cells from macaque
5173 PBMC using tetramers of the neutralization-sensitive
CAP206 6-month Env as well as the neutralization-resistant
CAP206 30-month Env. Memory cells (CD20+ and CD27+) that
bound the 6-month, but not the 30-month, Env were sorted
into individual wells of a 96-well plate (Figure 3A). The frequency
of 6-month Env-specific memory B cells was 0.07% (Figure 3A).
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Figure 1. Immunization with T/F Envs Elicits Tier-2 Neutralization
(A) Neighbor-joining phylogenic tree of isolated env sequences from South African HIV-1-infected individual CAP206 from the time of transmission to 39 months
post-infection. Red boxes indicate envs selected for production of recombinant immunogens.
(B) Immunization regimen; six rhesus macaques immunized seven times every 6 weeks with a swarm of seven CAP206 Envs. Plasma samples were collected
2 weeks post-immunization.
(C) Plasma neutralization of heterologous Tier-1 and autologous Tier-2 viruses before immunization (week 0) and 2 weeks after the last immunization (week 38)
measured as the plasma dilution at which relative luminescence units (RLUs) were reduced 50% compared to control wells in the TZM-bl neutralization assay
(yellow, ID50 > 20; orange, ID50 > 200; red, ID50 > 1,000).
(D) Plasma neutralization over the course of immunization for rhesus monkey number 5173 of the CAP206 autologous Tier-2 viruses (T/F, 2-month, 6-month,
12-month, 21-month, 24-month, and 30-month) in the TZM-bl neutralization assay. Dashed line indicates immunization time points.
See also Figures S1–S3.immunoglobulin (Ig) genes of the sorted memory B cells identi-
fied two mAbs (DH427 and DH428) that specifically bound the
CAP206 6-month Env in ELISA (Figure 3B). As expected from
their sensitivity to changes at position 463, DH427 and DH428
competed for binding of soluble CD4 to CAP206 6-month Env
(Figure 3C). Sequences of the heavy- and light-chain Ig genes
showed that DH427 and DH428 are two members of the same
B cell clonal lineage, which used the rhesus orthologs of the hu-
man VH 3-23 and Vl 2-11 genes (Figures 3D and S4). Members of
the DH427 lineage have short HCDR3s (10 aas); the variable
heavy regions were mutated 4.5% in DH427 and 2.4% in
DH428 (Figure 3D).DH427 CD4bs Antibody Lineage Neutralized the Tier-2
CAP206 6-Month Virus
DH427 and DH428 neutralized the 6-month virus but did not
neutralize any of the other autologous or heterologous viruses
tested (Figures 4A and S5). Moreover, DH427 and DH428 did
not neutralize the CAP206 6-month virus with an N463 mutation,
recapitulating the pattern of neutralization observed in the 5173
plasma (Figure 4A).
The CAP206 6-month Env lacked a glycosylation site in
V5; introduction of a glycosylation site in V5 of the CAP206
6-month Env eliminated neutralization by both 5173 plasma
and DH427 lineage antibodies. The CAP206 TF Env also lackedCell Reports 14, 43–54, January 5, 2016 ª2016 The Authors 45
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Figure 2. Glycosylation of the V5 Loop
Blocks Autologous Tier-2 Neutralization
(A) Highlighter plot showing mutations in the Env
that occur in the longitudinal immunogens from the
T/F sequence.
(B) Amino acid alignment of the CAP206 V5
regions.
(C) Macaque 5173 plasma neutralization of wild-
type and mutant CAP206 6-month viruses over the
course of immunization measured as the plasma
dilution at which RLUs were reduced 50%
compared to control wells in the TZM-bl neutrali-
zation assay.
(D) CAP206 plasma neutralization of autologous
2-month and 12-month viruses compared with
12-month reverted mutant viruses over the course
of infection.a glycosylation site in V5, but the loop was five amino acid resi-
dues longer (Figure 4B). This virus resisted neutralization by
DH427 and DH428; deletion of the five residues in V5 of the
CAP206 TF virus to match the 6-month virus made it sensitive
to both antibodies (Figure 4C). Thus, both the presence of glyco-
sylation sites and the length of the V5 loop restricted CAP206 vi-
rus neutralization by DH427 and DH428.
Maturation of the DH427 Clonal Lineage
For an analysis of the evolution of the DH427 antibody lineage,
we inferred the intermediate (I1) and the unmutated common
ancestor antibodies of DH427 and DH428. The I1 and mature
antibodies specifically and exclusively bound the CAP206
6-month Env, but there was no detectable binding of this partic-
ular unmutated common ancestor candidate antibody to any of
the recombinant CAP206 Envs (Figures 5A and S6). We showed
that light-chain mutations between the unmutated common
ancestor and I1 determined the difference in DH427/DH42846 Cell Reports 14, 43–54, January 5, 2016 ª2016 The Authorsbinding by pairing the unmutated com-
mon ancestor heavy chain with the I1 light
chain and vice versa. Only the former had
detectable affinity (Figure 5B). Failure of
the inferred DH427 unmutated common
ancestor to bind the immunogen led us
to consider whether one or more of the
amino acid residues considered to have
come from somatic hypermutation (SHM)
might instead be germline encoded in an
as yet undiscovered rhesus macaque Vl
allelic variant, leading to an incorrect
inference for the unmutated common
ancestor.
We examined the germline IGLV2-F
sequence in macaque 5173 by targeted
genomic amplification and sequencing
of extracted genomic DNA (Figure S7).
Sequencing of individual colonies de-
tected an IGLV2-F allele (IGLV2-F*02) that
shared three of the four residues that we
had considered mutated in I1 (Figure 5C).We then sequenced the IGLV2-F allele in the five remaining ani-
mals in the immunization study and found IGLV2-F*02 in the
genomic DNA of all five (Figure S6C). From these results, we de-
signed a new unmutated common ancestor (UCA2) by incorpo-
rating the new germline light-chain allele. We found that inferred
UCA2 bound the 6-month Env, indicating that UCA2 was the
authentic initiator of the DH427/DH428 B cell lineage (Figure 5D).
The UCA2 antibody did not neutralize the 6-month virus,
but both DH471 I1 and the chimeric (unmutated common
ancestor VH: I1VL) antibody did neutralize this virus (Fig-
ure 5E). These results indicated that autologous neutralization
activity required a specific sequence of light-chain affinity
maturation.
DH427 Unmutated Common Ancestor Reacts with Host
Protein FAM21C
Two macaques (5160 and 5184) had weak autologous nAb
responses, one (5173) had a robust autologous nAb response,
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Figure 3. Isolation of Antibodies that Specif-
ically Target the CAP206 6-Month Env
(A) PBMCs frommacaque 5173 at week 38 after the
seventh immunization were used for sorting CD20+
CD27+ memory B cells that specifically reacted
with the 6-month Env and not the 30-month Env.
(B) Binding of isolated mAbs DH427 and DH428 to
the seven CAP206 Env immunogen proteins by
ELISA.
(C) Cross-competition of sCD4-Ig binding to the
CAP206 6-month Env by DH427, DH428, and RSV
antibody Synagis determined by ELISA.
(D) Genomic characteristics of DH427 and DH428.
See also Figure S4.and three (5165, 5167, and 5183) had no autologous nAb res-
ponse, yet all had received the same vaccine immunogen.
This variability in the response suggested that host factors
limited high levels of responses in the other five animals. To
examine the role of cross-reactivity with host antigens for the
development of Tier-2 nAbs, we tested each immunized ma-
caque’s plasma pre- and post-immunization for reactivity to
common auto-antigens recognized by individuals with autoim-
mune disease (Figure S7D). We did not detect significant anti-
body polyreactivity in plasma for any of the auto-antigens
tested.
Next, we tested the DH427 lineage for reactivity with the
same auto-antigens and did not detect reactivity (Figure S7E).
We then tested DH427 and the DH427 unmutated common
ancestor antibodies for reactivity to >9,400 human proteins
on a microarray (Figure 5F). We found that neither DH427
nor the unmutated common ancestor were polyreactive, but
the unmutated common ancestor did react strongly with a sin-
gle host protein Family of Sequence Similarity 21, Member C
(FAM21C; Figure 5F; Table S1). FAM21C is a member of the
WASH complex that is involved in intracellular trafficking (Go-
mez and Billadeau, 2009). These data raise the hypothesis that
reactivity with auto-antigens may have blocked the initial
maturation and/or expansion of DH427-like lineages in the
other five macaques while having the correct germline VL
allele.Cell Reports 14, 43–Structure of DH427 in Complex with
HIV-1 gp120
The DH427/DH428 vaccine-induced line-
age blocked CD4 binding and neutralized
an autologous Tier-2 virus, but its genetic
characteristics differed from those of
most CD4bs nAbs. We crystallized and
determined at 6.6 A˚ resolution the struc-
ture of the DH427 Fab in complex with a
recombinant variant of the ZM1766.66
gp120 that had the CAP206 6-month V5-
loop sequence. We also determined the
structures of the DH427 and DH428 Fabs
at 2.66 A˚ and 2.32 A˚ resolution, respec-
tively (Table S2).
The DH427 Fab associates with HIV
gp120 along an outer rim of the CD4-bind-ing surface. CDRH2 and CDRH3 contact the V5 loop, and CDRL1
and CDRL3 contact loop E (Figure 6A). The limited resolution did
not allow detailed description of side-chain interactions. We su-
perposed onto the gp120 core domain from our complex the
structure of the gp120 core domain bound with soluble CD4.
The bulk of the Fab was large enough to block CD4 binding,
even though their overlapping footprints differed substantially
(Figure 6B). In contrast, the CD4bs bnAb VRC01 contacts
conserved residues in the V5 loop and has more contacts in the
CD4bs than DH427, allowing for more-effective CD4 blocking
and broad antigen recognition (Figure 6B). Mutability of V5, at
the core of their contact, and a very frequently foundglycosylation
site at position 355 on loop E clearly accounted for the restricted
breadth of DH427andDH428. For example, the glycan at position
463would project directly into the face of the antibody (Figure 6C).
Thus, further affinity maturation would be unlikely to generate
much-greater neutralization breadth.
Superposition of the gp120 outer domain from its complex
with DH427 onto the homologous domain in the BG505 SOSIP
gp140 structure shows that the Fab would project laterally
from the periphery of the trimer (Figure 6D). DH427 is in almost
the same orientation as the CD4bs bnAb VRC01 but displaced
outward by about 25 A˚. This angle is also distinct from the proto-
typical Tier-1-neutralizing CD4bs mAb F105, which projects in a
more-axial direction, making it prone to steric hindrance on the
‘‘closed’’ trimers of Tier-2 viruses (Figure 6D).54, January 5, 2016 ª2016 The Authors 47
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Figure 4. DH427 and DH428 Neutralize the
Tier-2 CAP206 6-Month Virus
(A) Neutralization of the CAP206 6-month virus and
engineered glycosylation site mutant measured as
the antibody concentration at which RLUs were
reduced 50% compared to control wells (IC50) in the
TZM-bl neutralization assay (mg/ml).
(B) CAP206 T/F V5 sequence and mutated V5
sequence to match the 6-month Env. Red amino
acids were deleted.
(C) DH427 and DH428 neutralization of the T/F and
T/F mutant that had a V5 that matched the 6-month
Env in the TZM-bl neutralization assay (mg/ml; or-
ange, IC50 < 5.0; red, IC50 < 1.0).
See also Figure S5.DISCUSSION
Recent studies show that bnAb lineages can evolve out of autol-
ogous nAb lineages present early in HIV-1 infection (Doria-Rose
et al., 2014; Liao et al., 2013a; Wibmer et al., 2013). All HIV-1-in-
fected individuals produce autologous Tier-2 nAbs months after
transmission, but not all HIV-infected individuals go on to make
bnAbs (Bar et al., 2012; Doria-Rose et al., 2010; Gray et al.,
2009b; Kwong et al., 2013; Richman et al., 2003; Wei et al.,
2003). Thus, eliciting strain-specific nAbs that target neutraliza-
tion-resistant Tier-2 viruses can be a first step to develop bnAbs
during vaccination. CAP206 is an HIV-infected individual that
produced bnAbs targeting the MPER, but we found that the V5
loop was a target for autologous nAbs early after infection in
CAP206. Thus, in CAP206, the autologous nAb response was
unrelated to the bnAb response. Our finding that, after only
two immunizations with a swarm of CAP206 Envs, the CAP206
6-month variant of the TF Env induced in one of six rhesus ma-
caques potent autologous Tier-2 nAbs that targeted a similar
nAb epitope observed in CAP206 shows that vaccination with
gp140 oligomers can, in principle, also produce such antibodies.
However, that only three macaques had autologous nAbs, and
only one with high titers, contrasts with HIV infection, in which
virtually all HIV-infected individuals make autologous nAbs.
These studies raise several important issues for HIV vaccine
development.
First, our structural studies of DH427 CD4bs autologous nAb
demonstrated that DH427 neutralization was restricted to the
autologous virus because antibody recognition centers on the
V5 loop. Moreover, the mode of V5 contact prevented full
engagement of the CD4bs and explains why this lineage is un-
likely to achieve bnAb breadth with further affinity maturation.
Second, it is a conundrum that all HIV-infected individuals
make autologous nAbs and up to 50% make some level of
bnAbs, whereas no humans vaccinated with Envs have to date
made either autologous nAbs or bnAbs. All the macaques in
the group studied had the IGLV2-F germline allelic variant, and
thus, all had the required VL repertoire to respond to Env immu-
nization. One hypothesis is that there may be host control mech-
anisms for autologous nAbs in both macaques and humans and
that the responding macaque (5173) was permissive for release
of antibodies that can recognize a closed or Tier-2 envelope.
There was no reactivity with auto-antigens common in autoim-
mune disease by the plasma or DH427 lineage antibodies, but48 Cell Reports 14, 43–54, January 5, 2016 ª2016 The Authorsthe DH427 unmutated common ancestor antibody did react
with host protein FAM21C. This reactivity may have limited
expansion of this lineage in the other animals.
Broad neutralization appears only after years of persistent
infection, in part because breadth requires high levels of SHM,
even for those antibodies with relatively invariant Env contacts
(Kepler et al., 2014; Kwong and Mascola, 2012; Scheid et al.,
2009, 2011). Driving high SHM by vaccination is particularly diffi-
cult, because many highly mutated antibodies are disfavored by
the host immune system (Haynes and Verkoczy, 2014). DH427
lineage antibodies required SHM for neutralization, but they
were less than 5% mutated and were induced rapidly after
only two immunizations. Thus, the DH427 lineage achieved
potent Tier-2 autologous neutralization with minimal SHM.
Finally, HIV Env shifts from a ‘‘closed’’ to an ‘‘open’’ conforma-
tion when CD4 binds (Liu et al., 2008). In that transition, it ex-
poses epitopes concealed in the closed state. Any particular
Env is in equilibrium between closed and open (and probably
one or more intermediate) states (Julien et al., 2013; Pugach
et al., 2015). The key structural correlate of the distinction be-
tween Tier-1 and Tier-2 is whether this equilibrium is strongly
on the side of the closed conformation (Tier-2, primarily bnAb
site accessible) or more frequently toward the open conforma-
tion (strain-specific and non-neutralizing sites accessible). A
recent study demonstrated that a stabilized recombinant
native-like closed trimer Env (BG505 SOSIP.664) elicited nAbs
to the sequence-matched Tier-2 virus in rabbits and in three of
four macaques (Sanders et al., 2015). In the Sanders et al. study
in macaques, the titers of autologous nAbs ranged from 32 to
168, similar to the titers observed in an earlier study by Willey
et al. (40–113) and in the present study (25–437).The immunogen
used here was a trimeric Env, but not a variant (such as BG505
SOSIP.664) locked into a closed state by intentional modifica-
tion. Nonetheless, it elicited potent autologous nAbs, and in at
least the one lineage we have studied, those nAbs recognized
a site accessible of the surface of a Tier-2 virus and thus, by infer-
ence, on the surface of a closed trimer. Although the DH427 nAb
Env epitope appears to be too variable, both in the length of the
loops and in their potential for glycosylation, to be a target for
bnAbs, its proximity to the CD4bs and its dependence on similar
conformational parameters suggest that related vaccine
immunogens could also induce the germline precursors of
CD4bs bnAbs. Indeed, whereas most Env immunogens fail to
engage germline-reverted CD4bs-directed bnAbs, including
A B
C
D E
F
(legend on next page)
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Figure 6. Structure of DH427 in Complex
with HIV gp120
(A) DH427 contact sites within the V5 loop and loop
E (DH427, orange; gp120, gray; V5 loop, red; loop
E, purple; PDB 5F6J).
(B) DH427 in complex with gp120 core with VRC01
(PDB 3NGB) and CD4 (PDB 1GC1) molecule su-
perimposed (DH427, orange; gp120, gray; V5 loop,
red; VRC01, pink; CD4 molecule, yellow).
(C) Co-crystal structure of DH427 and HIV Env
with N-acetylglucosamine (GlcNAc) displayed as
spheres at the V5 glycan site that would interfere
with DH427 heavy chain.
(D)ModelingofDH427,VRC01,andF105 (PDB3HI1)
onto the high-resolution cryo-EM trimer structure of
BG505 SOSIP (BG505 SOSIP trimer [PDB 3J5M],
gray) side view (top) and top view (bottom).
See also Table S2.germline-reverted VRC01 (McGuire et al., 2013; Zhou et al.,
2010), eliminating glycosylation sites in loop D and V5, as
in the CAP206 6-month variant that induced the DH427 lineage,
allowedDH427 germline-Env binding and B cell lineage develop-
ment. Incorporating these sites, along with truncation or deletion
of V5, into future Env immunogensmay have a useful role in prim-Figure 5. Reconstruction of the DH427 Clonal Lineage
(A) Binding of DH427, DH428, and the inferred intermediate (I1) and unmutated common ancestor (UCA) t
tibodies were immobilized on a CM5 chip, and protein was flowed over at 100 mg/ml.
(B) Binding of the DH427 I1 and I1-UCA hybrids to the CAP206 6-month Env measured by ELISA.
(C) Amino acid alignment of the germline IGVL2-F*01 with DH427 UCA and I1 antibodies comparedwith IGVL
genomic DNA from animal 5173.
(D) Binding of newly designed DH427 UCA (DH427 UCA2) to the CAP206 6-month Env by SPR. DH427 UCA
flowed over at the indicated concentrations.
(E) Neutralization of DH427 I1, UCA2, and chimeric (UCA VH:I1VL) of the CAP206 6-month virus and glycos
centration (mg/ml) at which RLUs were reduced 50% compared to control wells (IC50) in the TZM-bl neutral
(F) Reactivity of DH427UCA2 and DH427 on a panel of 9,400 human proteins tested using a ProtoArray micro
values are relative fluorescent signal intensity. Each dot represents an average of duplicate array proteins. Da
as cutoff for reactivity.
See also Figures S6 and S7 and Table S1.
50 Cell Reports 14, 43–54, January 5, 2016 ª2016 The Authorsing B cell responses to the CD4bs. More-
over, modifying the CAP206 Env to have a
more-closed structure by SOSIP modifi-
cation may also increase immunogenicity.
Such structural considerations coupled
with understanding host control of induc-
tion of nAbs should lead to design of stra-
tegies for inducing autologous nAbs to
Tier-2 HIV with greater heterologous
neutralization breadth (Liao et al., 2013a).
EXPERIMENTAL PROCEDURES
Donor Subject
CAP206 is an HIV-1 subtype C chronically infected
individual used for this study. This participant was
part of the CAPRISA 002 Acute infection cohort
whose antibody neutralization profile has been
studied since the point of seroconversion (Gray
et al., 2007, 2009b). This study was approved by
the IRBs of the Universities of KwaZulu Natal andWitwatersrand in South Africa and Duke University. Written informed consent
was obtained from all study participants.
Design andProduction of Recombinant gp140ProteinsDerived from
CAP206
The cloning and sequencing of env sequences was performed as described
previously from longitudinal samples from CAP206 (L.M., unpublished data;o the CAP206 6-month Env measure by SPR. An-
2-F*02 allele discovered by sequencing the IGVL2-F
2 was immobilized on a CM5 chip, and protein was
ylation site mutant measured as the antibody con-
ization assay.
chip compared with a nonreactive rhesus mAb. Axis
shed lines indicate 500-fold signal/background ratio
Gray et al., 2007; Keele et al., 2008). The single TF and six mutant clones from
later time points (CAP206 TF, 2 months, 6 months, 12 months, 21 months,
24 months, and 30 months) were selected for production as soluble gp140
trimeric immunogens. The recombinant Envs were expressed in 293T cells
and purified using lectin and size-exclusion chromatography as described pre-
viously (Liao et al., 2013b).
Immunization of Rhesus Macaques
Six rhesus macaques each received seven intramuscular immunizations at 6-
week intervals with seven CAP206 Env immunogens (100 mg total) in MF59
adjuvant (Novartis). Blood samples were collected 2 weeks after each immu-
nization. All rhesus macaques were housed at Bioqual. All rhesus macaques
were maintained in accordance with the Association for Assessment and
Accreditation of Laboratory Animals with the approval of the Animal Care
and Use Committees of the NIH and Harvard Medical School. Research was
conducted in compliance with the Animal Welfare Act and other federal stat-
utes and regulations relating to animals and experiments involving animals
and adheres to principles stated in the Guide for the Care and Use of Labora-
tory Animals, NRC Publication, 2011 edition.
Antibody Isolation
CAP206 6-month gp140 and CAP206 30-month gp140 proteins were fluores-
cently labeled with AF647 and BV421 (Invitrogen), respectively. Peripheral
blood mononuclear cells (PBMCs) from rhesus monkey 5173 at week 38
were stained with fluorescently labeled antibodies for cell surface markers
and both CAP206 Envs. Memory B cells that were stained positive for the
CAP206 6-month Env and not the CAP206 30-month Env were sorted into sin-
gle wells of 96-well PCR plates containing RT-PCR buffer as previously
described (Wiehe et al., 2014). Antibody variable heavy and variable light
genes were amplified using nested PCR and purified and sequenced as
described previously (Wiehe et al., 2014). VDJ arrangements, clonal related-
ness, and identification of the intermediate and unmutated common ancestor
were inferred using previously described computational methods (Kepler,
2013; Munshaw and Kepler, 2010).
Sequencing of Germline Variable Region
Genomic DNA was isolated from all six animals from PBMCs at 2 weeks af-
ter the first immunization (QIAmp DNA Blood mini kit; QIAGEN). IGLV2-F se-
quences were amplified using two independent primer sets. To ensure
amplification of non-rearranged variable sequences, both primer sets
reverse primers aligned to sequences present in the non-coding genomic
DNA downstream the V-recombination site. The forward primer for set 1
resided in the IGV2-F leader sequence and upstream of the leader in set
2. The PCR fragments were cloned into a pcDNA2.1 (TOPO-TA kit; Life
Technologies) and transformed into bacteria for sequencing of individual
colonies.
Expression of Recombinant Antibodies
Transient small-scale expression of antibodies was achieved by assembling
VH, VK, or VL sequences with linear cassettes that contain the CMV pro-
moter, respective Ig constant region, and poly A signal sequence using over-
lapping PCR and transfection into 293T cells as described previously (Liao
et al., 2009). Supernatants were directly used to screen for binding of Env an-
tigens in ELISA.
For production of purified recombinant mAbs, the VH and VL genes from
DH427 lineage antibodies were cloned into expression vectors and expressed
and purified as described previously (Liao et al., 2011). Site-directed mutagen-
esis of antibody geneswas performed using theQuikchange II lighteningmulti-
site-directed mutagenesis kit (Agilent).
ELISA binding of transiently transfected supernatants and purified re-
combinant mAbs was performed as described previously (Liao et al.,
2011).
Surface Plasmon Resonance
Surface plasmon resonance assays were performed on a BIAcore 4000 in-
strument, and data analysis was performed with BIAevaluation 4.1 soft-
ware (BIAcore). Anti-gp120 mAbs or sCD4 in 10 mM Na-acetate buffer(pH 4.5) were directly immobilized to CM5 sensor chips using a standard
amine coupling protocol for protein immobilization. Purified CAP206 Env
glycoproteins were flowed over CM5 sensor chips at concentrations of
2–100 mg/ml. Binding of CAP206 envelope proteins was monitored in
real time at 25C with a continuous flow of PBS (150 mM NaCl, 0.005%
surfactant P20 [pH 7.4]) at 10–30 ml/min (Alam et al., 2011; Gao et al.,
2014).
Neutralization Assays
Neutralization activities of animal plasma and purified antibodies were deter-
mined by the TZM-bl cell-based neutralization assay (Sarzotti-Kelsoe et al.,
2014). Tier phenotyping of the pseudoviruses was assayed by sensitivity to
a pool of HIV-infected serum as described previously (Seaman et al., 2010).
Antibody Reactivity with Host Proteins
The polyreactivity of the DH427 lineage was assayed in the AtheNA multi-lyte
system (Zeus Scientific). The rhesus mAbs were also tested for reactivity with
human host cellular antigens using ProtoArray 5 microchip (Life Technologies)
compared to a rhesus isotype-matched control antibody as described previ-
ously (Yang et al., 2013).
Expression and Purification of Proteins for Crystallization
The heavy- and light-chain variable and constant domains of the DH427 and
DH428 Fabs were cloned into the pVRC-8400 expression vector using Not1
and Nhe1 restriction sites and the tissue plasminogen activator signal
sequence. The C terminus of the heavy-chain constructs contained a non-
cleavable 63 histidine tag. Fabs were expressed and purified as described
previously (Fera et al., 2014).
The codon-optimized synthetic construct of the ZM176.66 HIV-1 subtype C
gp120 containing aa 41–492 (HXB2 numbering)DV123 (core) was produced by
GenScript with an N-terminal 63-histidine tag and inserted into the pVRC-
8400 expression vector as described for Fabs. The V5 loop of this gp120
core was mutated to that of the CAP206 6-month envelope by site-directed
mutagenesis using manufacturer’s protocols (Stratagene) and expressed in
293S GnTi-suspension adapted cells using linear PEI. After 5 days of expres-
sion, supernatants were clarified by centrifugation and passed over galanthus
nivalis lectin resin pre-equilibrated with 13 PBS. Bound protein was washed
with 13 PBS and eluted with 13 PBS and 500 mMmethyl a-D mannopyrano-
side. The glycoprotein was then deglycosylated overnight at 37C with Endo
H in a buffer of 50 mM sodium acetate (pH 6.0), 5 mM EDTA, 500 mM NaCl,
1 mg/ml leupeptin, and 1 mg/ml aprotonin. Deglycosylated gp120 core was
then purified by gel filtration chromatography in buffer B (2.5 mM Tris [pH
7.5], 350 mM NaCl, and 0.02% sodium azide) using a superdex 200 analytical
column (GE Healthcare). To make the complex for co-crystallization, DH427
and the ZM176.66 gp120 mutant were mixed in a 1.2:1 molar ratio and incu-
bated for at least 1 hr before passing over a superdex 200 preparatory column
(GE Healthcare) in buffer B. Fractions corresponding to the complex were
combined and concentrated to 10 mg/ml for co-crystallization trials.
Crystallization, Structure Determination, and Refinement
All His-tagged Fabswere crystallized at15mg/ml, and the DH427/ZM176.66
mutant gp120 core complex was crystallized at 10 mg/ml. Crystals were
grown in 96-well format using hanging drop vapor diffusion and appeared after
24–48 hr at 20C. DH427 crystals were obtained in a condition of 20% polyeth-
ylene glycol (PEG) 2K monomethyl ether (MME), 100 mM sodium citrate (pH
4.0), and 100 mM NaCl; and DH428 crystals were grown over a reservoir of
40% PEG 400 and 100 mM sodium acetate (pH 5.0). Initial crystals of
DH427/gp120 core complex were obtained in a condition of 1.5 M ammonium
sulfate and 100 mM Tris (pH 8.0) and were optimized to 24-well format to
obtain larger crystals. All crystals were harvested and cryoprotected by the
addition of 20%–25% glycerol to the reservoir solution and then flash cooled
in liquid nitrogen. Crystals of complex were cryoprotected with a series of
different cryoprotectants including 15%–30% glycerol, 15%–30% ethylene
glycol, and 1 or 2 M sodium malonate; however, the best diffraction was ob-
tained with 20%–30% glycerol or ethylene glycol as the cryoprotectant.
Diffraction data were obtained at 100 K from beam lines 24-ID-C and 24-
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from individual crystals (two crystals for DH427 and one crystal for DH428)
were processed with HKL2000 (Otwinowski and Minor, 1997) and XDS
(Kabsch, 2010) for DH427 and DH428, respectively. Molecular replacement
calculations for the free Fabs were carried out with PHASER (McCoy, 2007),
using I3.2 from the CH103 lineage (PDB ID 4QHL) as the starting model. The
I3.2 model was separated into its variable and constant domains for the
DH427 and DH428 Fab structure determinations. Crystals of the DH427 and
DH428 Fabs had four and one molecules per asymmetric unit, respectively.
For both Fabs, subsequent refinement steps were carried out with PHENIX
(Adams et al., 2010), and all model modifications were carried out with Coot
(Emsley and Cowtan, 2004). During refinement, maps were generated from
combinations of positional, group B-factor, and TLS (translation/ libration/
screw) refinement algorithms. Secondary-structure restraints were included
at all stages for all Fabs; noncrystallographic symmetry restraints were applied
to the DH427 Fab throughout refinement.
Data from multiple crystals of the DH427/gp120 core complex were pro-
cessed using HKL2000 (Otwinowski and Minor, 1997), and molecular replace-
ment calculations were carried out with PHASER (McCoy, 2007), using the
refined DH427 coordinates and gp120 core from the VRC01/gp120 complex
(PDB ID 4LST) as the starting models. DH427 was separated into its variable
and constant domains for structure determinations. There were twomolecules
per asymmetric unit. The resulting electron density map for the complex was
further improved by solvent flattening, histogram matching, and noncrystallo-
graphic symmetry averaging using the program Parrot (Winn et al., 2011).
Phase combination was disabled in these calculations. After density modifica-
tion, rigid-body refinement was performed using Refmac in Coot.
Structure validations were performed periodically during refinement using
the MolProbity server (Davis et al., 2007). The final refinement statistics are
summarized in Table S1.
Protein Structure Analysis and Graphical Representations
The core domain of the chimeric ZM176.66 gp120 core mutant designed in our
study was superposed on other gp120 cores from the PDB by least-squares
fitting in Coot. All graphical representations with protein crystal structures
were made using PyMol.
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